This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MaxCyte (MXCT) delivered earnings and revenue surprises of 35.71% and 27.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -9.68% and 71.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
MaxCyte (MXCT) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
MaxCyte (MXCT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 85% in MaxCyte (MXCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why
by Zacks Equity Research
MaxCyte (MXCT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
MaxCyte (MXCT) delivered earnings and revenue surprises of 35.71% and 46.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Qiagen (QGEN) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Qiagen (QGEN) delivered earnings and revenue surprises of 2% and 0.22%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 0% and 1.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
UniQure (QURE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of -59.80% and 79.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 8.97% and 43.96%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
MaxCyte, Inc. (MXCT) Loses 18.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
MaxCyte, Inc. (MXCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
MaxCyte, Inc. (MXCT) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
MaxCyte, Inc. (MXCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 33.33% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Vanda Pharmaceuticals (VNDA) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of -40% and 8%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MaxCyte, Inc. (MXCT) Moves 9.3% Higher: Will This Strength Last?
by Zacks Equity Research
MaxCyte, Inc. (MXCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
MaxCyte, Inc. (MXCT) delivered earnings and revenue surprises of 0% and 6.76%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 55.43% and 714.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Akoya Biosciences (AKYA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akoya (AKYA) delivered earnings and revenue surprises of -38.24% and 5.69%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?